Literature DB >> 9275953

Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions.

J P McCormack1, M Levine, R E Rangno.   

Abstract

Long-term population-based studies have identified and quantified risk factors for cardiovascular and cerebrovascular (CCV) events. In addition, a number of well-designed clinical trials have shown that various drug therapies that reduce these factors decrease the risk of some CCV events. In the practice of evidence-based medicine, data from clinical trials should inform treatment decisions. The clinician and patient, however, are faced with the difficult task of assessing the patient's particular risk and likelihood of benefit on the basis of the results of large, randomized trials. To assist clinicians and their patients in arriving at treatment decisions, the authors provide simple nomograms for estimating the risk of a CCV event for an individual patient and suggest an approach to estimating the potential benefit of drug therapy for primary prevention.

Entities:  

Mesh:

Year:  1997        PMID: 9275953      PMCID: PMC1227917     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  16 in total

1.  Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease.

Authors:  S Ebrahim; G D Smith
Journal:  BMJ       Date:  1997-06-07

2.  Drug treatment of hypertension in the elderly: a meta-analysis.

Authors:  J T Insua; H S Sacks; T S Lau; J Lau; D Reitman; D Pagano; T C Chalmers
Journal:  Ann Intern Med       Date:  1994-09-01       Impact factor: 25.391

3.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

Review 4.  Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs.

Authors:  K G Marshall
Journal:  CMAJ       Date:  1996-08-15       Impact factor: 8.262

Review 5.  Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention.

Authors:  F E Kuhn; C E Rackley
Journal:  Arch Intern Med       Date:  1993-12-13

6.  Meaningful interpretation of risk reduction from clinical drug trials.

Authors:  J P McCormack; M Levine
Journal:  Ann Pharmacother       Date:  1993-10       Impact factor: 3.154

7.  Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.

Authors:  R B D'Agostino; P A Wolf; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

8.  Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?

Authors:  C D Naylor; E Chen; B Strauss
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?

Authors:  J E Hux; C D Naylor
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

View more
  4 in total

1.  Patients offered treatment for CHD need full information to make decision.

Authors:  J P McCormack; M Levine; R E Rangno; P McCormack
Journal:  BMJ       Date:  1998-03-28

2.  Using disease risk estimates to guide risk factor interventions: field test of a patient workbook for self-assessing coronary risk.

Authors:  J Michael Paterson; Hilary A Llewellyn-Thomas; C David Naylor
Journal:  Health Expect       Date:  2002-03       Impact factor: 3.377

3.  Comparative accuracy of cardiovascular risk prediction methods in primary care patients.

Authors:  A F Jones; J Walker; C Jewkes; F L Game; W A Bartlett; T Marshall; G R Bayly
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 4.  Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians.

Authors:  Stacey Sheridan; Michael Pignone; Cynthia Mulrow
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.